Semaglutide Trial Indicates Reduced Heavy Drinking in Patients with Alcohol Use Disorder and Obesity

A randomized, double-blind, placebo-controlled trial has shown that once-weekly semaglutide significantly reduced heavy-drinking days in adults with both alcohol use disorder and obesity. The study, originally published in The Lancet, involved 108 participants and demonstrated a substantial decrease in heavy drinking compared to the placebo group. These findings suggest a promising new therapeutic approach for this specific patient population.